Abstract 1553P
Background
The era of precision and immuno-oncology has revolutionised treatment paradigms however access and cost has highlighted global disparities. Following authorisation by the European Medicines Agency, reimbursement processes in each country vary. On the island of Ireland, the National Institute for Health and Care Excellence (NICE) approvals are used in Northern Ireland and an independent Health Technology Assessment agency make recommendations to the Health Service Executive (HSE) in the Republic. We aimed to compare the time to reimbursement in both systems.
Methods
All systemic anti-cancer therapies for solid organ malignancies which received marketing authorisation by the EMA between 06/2018-06/2023 were included. Identified agents were cross-referenced with therapies reimbursed by the Cancer Drugs Fund and NICE (UK), and by the HSE (Ireland). The time from EMA authorisation to reimbursement in each country was compared. Clinical trial data supporting approval were reviewed, including overall survival (OS) and health related quality of life data (HRQoL).
Results
During this period, 90 treatments received marketing authorisation by the EMA, 58 were reimbursed in Ireland and 88 in the UK. Of the treatments reimbursed in both the UK and Ireland, the EMA recommended 23 of these prior to 06/2018. The median time from EMA approval to patient access was 12 months in the UK and 27.5 months in Ireland. This varied depending on the malignancy. Phase III data was available for 85% (97/114) of treatments approved by the EMA. An OS benefit was seen in 59% (65/114) of treatments. Of the remaining 41% of treatments, 30% (34/114) did not demonstrate an improvement in OS, with >50% of these pertaining to molecular targets in small patient subsets. OS data was not mature in the remaining 11%. HRQoL data are available for 91% (104/114) of treatments that received EMA authorisation, although in most cases was published after the EMA decision.
Conclusions
Reimbursement of EMA approved systemic anticancer treatments is taking more than twice as long in Ireland compared to Northern Ireland and UK processes. Estimated increases in cancer diagnoses over the next decades highlights the importance of improving the current drug reimbursement processes to allow patients timely access to novel therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
O.M. Fitzpatrick: Non-Financial Interests, Personal, Other, Support to attend meeting: Pfizer, Servier, AstraZeneca. M.R. Khan: Non-Financial Interests, Personal, Other, Travel: Pfizer; Non-Financial Interests, Personal, Officer, Travel: Novartis. C.S. McNevin: Non-Financial Interests, Personal, Other, Support to attend meeting: GSK, Takeda. D.J. McMahon: Non-Financial Interests, Personal, Other, Travel: Takeda; Financial Interests, Institutional, Funding: Pfizer, Roche. G.M. O'Kane: Financial Interests, Personal, Other, Honoraria and consulting: AstraZeneca, Roche, Servier, MSD, Incyte, Eisai; Financial Interests, Institutional, Research Grant: Roche, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10